Teleflex INC

Teleflex Incorporated announced an accelerated share repurchase program to buy back $250 million of its common stock, funded by proceeds from a recent business divestiture.

Teleflex announced its second quarter 2026 financial results, highlighting strong performance in Vascular and Surgical businesses, but revised revenue outlook due to integration delays in the Vascular Intervention business.

Teleflex Incorporated has filed an amendment to its Form 8-K to include unaudited pro forma financial information following the completion of its OEM business divestiture.

Teleflex Incorporated has successfully issued $500 million in 5.875% senior notes due 2032 to support its capital structure.

Teleflex Incorporated has awarded a $600,000 restricted stock unit grant to Interim CEO Stuart A. Randle for his extended service and leadership contributions.

Teleflex Incorporated is launching a private offering of $500 million in Senior Notes due 2032 to redeem its outstanding 4.625% Senior Notes due 2027.

Teleflex Incorporated's Q2 2026 Form 10-Q filing details strong revenue growth driven by the VI Business acquisition and strategic divestitures, alongside significant restructuring efforts.

Teleflex Incorporated reported a net loss for the first quarter of 2026, impacted by restructuring charges and strategic divestitures, despite an increase in net revenues driven by the BIOTRONIK VI Business acquisition.

Teleflex Incorporated reported a significant net loss of $408.9 million for the third quarter of 2025, primarily driven by a $403.9 million goodwill impairment charge related to its Interventional Urology North America unit and a $100 million asset impairment for the Titan SGS product line.

Teleflex Incorporated announced a significant increase in net income and EPS for the second quarter and year-to-date periods, driven by strategic cost management and favorable foreign currency hedging, despite mixed revenue performance and ongoing restructuring efforts.

Teleflex Incorporated's Q1 2025 results reveal a revenue decrease, strategic separation plans, and an acquisition to bolster its interventional product portfolio.

Teleflex's third-quarter results show a slight revenue increase but are impacted by restructuring costs and challenges in the UroLift market.

Teleflex Incorporated reported a significant net loss in 2025 driven by substantial impairment charges related to its strategic divestitures, while continuing operations saw revenue growth from a key acquisition.

Teleflex Incorporated's 10-K filing reveals plans for a strategic separation into two companies, alongside a $240 million goodwill impairment charge and ongoing restructuring efforts impacting its financial performance for the year ended December 31, 2024.

Teleflex Incorporated's 10-K filing details the company's registered securities, including common stock, and outlines key aspects of its capital structure and corporate governance.

Director Stuart A. Randle reported the acquisition of restricted stock units and stock options alongside a tax-related share withholding.

Teleflex Incorporated CEO Jason R. Weidman was granted 53,983 restricted stock units and 26,071 stock options.

Director Jaewon Ryu was granted 1,090 restricted stock units and 2,397 stock options as part of the Teleflex 2023 Stock Incentive Plan.

Director Andrew Krakauer was granted 1,090 restricted stock units and 2,397 stock options as part of the 2023 Stock Incentive Plan.

Teleflex Incorporated director Gretchen R. Haggerty was granted 1,090 restricted stock units and 2,397 stock options.

Teleflex Incorporated Director Candace H. Duncan was granted 1,090 restricted stock units and 2,397 stock options.

Teleflex Incorporated has issued its definitive proxy statement for the May 15, 2026 Annual Meeting of Stockholders, detailing proposals for director elections, advisory vote on executive compensation, and ratification of its accounting firm.

Teleflex Incorporated announces its 2025 Annual Meeting, urging shareholders to vote on key proposals including the election of directors and executive compensation.

Teleflex Incorporated announces its 2025 annual meeting of stockholders to be held on May 9, 2025, featuring proposals on director elections, executive compensation, auditor ratification, and a stockholder proposal.

Teleflex Incorporated will hold its annual meeting of stockholders on May 3, 2024, to vote on director elections, executive compensation, auditor ratification, and a stockholder proposal.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 8.7% of Teleflex Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 2,324,576 shares, representing 5.25% of Teleflex Inc.'s common stock, as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 5.56% in Teleflex Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Teleflex Inc. common stock following an internal realignment.

AQR Capital Management, LLC and its parent company have reported a 4.35% beneficial ownership stake in Teleflex Inc. as of December 31, 2025.

Morgan Stanley and its subsidiary, Atlanta Capital Management, have each reported reducing their beneficial ownership in Teleflex Inc. to below the 5% threshold.